Maria A. Simakova

Maria A. Simakova

Auto-generated profile, based on publicly available information

Maria A. Simakova

Almazov National Medical Research Centre

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2023 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
VRV. A. Ryabkov
V. A. Ryabkov
NVN. N. Vezikova
N. N. Vezikova
NGNatalia Sergeevna Goncharova
Natalia Sergeevna Goncharova
MSM. A. Simakova
M. A. Simakova
OMOlga Moiseeva
Olga Moiseeva
In managing care for patients with rare, rapidly progressive pathologies such as pulmonary hypertension (PH) and chronic thromboembolic hypertension (CTEPH), early diagnosis and speed of routing are of particular importance. Reducing the time spent on patient routing reduces the risk of disease progression, the rate of hospitalizations, and thereby the socioeconomic burden of the disease.In the Republic of Karelia, an algorithm for routing patients with PH and CTEPH has been created, which is an example of a successful healthcare management.

1 December 2021 in Thrombosis Research
Verified
Journal Article
Closed access
OMO. Melnichnikova
O. Melnichnikova
MSM. Simakova
M. Simakova
OMOlga Moiseeva
Olga Moiseeva
INI. Nazarova
I. Nazarova
NKNataliya Klyaus
Nataliya Klyaus
TVT. Vavilova
T. Vavilova

25 December 2023 in Complex Issues of Cardiovascular Diseases
Verified
Journal Article
Open access
PDF file
АКАндрей Александрович Карпов
Андрей Александрович Карпов
МСМария Александровна Симакова
Мария Александровна Симакова
Pavel DocshinPavel Docshin
Pavel Docshin
YZYuliya I. Zhilenkova
Yuliya I. Zhilenkova
LSLeonid Shilenko
Leonid Shilenko
OMOlga Moiseeva
Olga Moiseeva
HighlightsIL-8 and MCP-1 have a significant role in the CTEPH pathogenesis, which indicates the importance of nonspecific immunity in the formation and progression of CTEPH. The coupling between cytokines and hemodynamic parameters, cardiac structural changes and plasma biochemical parameters were determined. AbstractBackground. Chronic thromboembolic pulmonary hypertension (CTEPH) pathogenesis is complex and not fully understood. Particular attention to the microvascular damage genesis in CTEPH is given to aseptic inflammation, which in turn could be mediated through various molecular mechanisms. According to the conflicting and incomplete data on changes in the profile of factors controlling inflammation in CTEPH, research in this field would identify new therapeutic targets for the prevention and treatment of CTEPH.Aim. To study the profile of plasma proinflammatory cytokines in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and evaluate the coupling of these cytokines with the main morphofunctional and laboratory values of the disease severity.Methods. 34 patients with CTEPH were included in this study. To characterize the group, the following methods were used: echocardiographic examination, catheterization of the right cardiac chambers. Biomarkers of heart failure, systemic inflammation, as well as erythropoiesis and iron metabolism were assessed in all patients. The control group included 10 donors. To study the proinflammatory cytokine profile in plasma, interleukins (IL) 6, 8, 18, monocyte chemoattractant protein-1 (MCP-1) and matrix metalloproteinase 9 were determined using standard enzyme-linked immunosorbent assay (ELISA) kits.Results. Hemodynamic and morphofunctional changes in the pulmonary circulation specific to pulmonary hypertension were determined with catheterization of the right cardiac chambers and echocardiography. During plasma proinflammatory cytokines analysis, a significant increase in the level of IL-8 (p = 0.030) and MCP-1 (p = 0.031) in CTEPH group compared to the control group was observed. No significant differences for other analyzed markers were found. In the elaboration of the correlation analysis, moderate inverse coupling between proinflammatory markers and hemodynamic parameters characterizing the CTEPH severity were revealed, as well as positive correlations with parameters of remodeling of the right cardiac chambers and iron metabolism.Conclusion. The increased levels of IL-8 and MCP-1 in patients with CTEPH identified in the present study indicate a significant role of nonspecific immunity in the formation and progression of CTEPH. The coupling between cytokines and hemodynamic parameters, structural cardiac changes and plasma biochemical parameters were determined. Based on the obtained data, it is possible to develop new medicinal substances, targeting towards proinflammatory cytokines, their receptors and signaling pathways.

16 February 2024 in Life
Verified
Journal Article
Open access
PDF file
NGNatalia Sergeevna Goncharova
Natalia Sergeevna Goncharova
KLKirill Lapshin
Kirill Lapshin
ABAelita Berezina
Aelita Berezina
MSMaria Simakova
Maria Simakova
AMAlexandr Marichev
Alexandr Marichev
OMOlga Moiseeva
Olga Moiseeva
Introduction: The predictive value of the risk stratification scales in elderly patients with IPAH might differ from that in younger patients. It is unknown whether young and older IPAH patients have the same survival dependence on PAH-specific therapy numbers. The aim of this study was to evaluate the prognostic relevance of risk stratification scales and PAH medication numbers in elderly IPAH patients in comparison with young IPAH patients. Materials and methods: A total of 119 patients from a prospective single-center PAH registry were divided into group I < 60 years old (n = 89) and group II ≥ 60 years old (n = 30). ESC/ERS, REVEAL, and REVEAL 2.0 risk stratification scores were assessed at baseline, as well as H2FpEF score and survival at follow-up. Results: During a mean follow-up period of 2.9 years (1.63; 6.0), 42 (35.3%) patients died; at 1, 2, 3, 5, 7, and 10 years, survival was 95%, 88.6%, 78.5%, 61.7%, 48.5%, and 33.7%, respectively. No survival differences were observed between the two groups, despite the use of monotherapy in the elderly patients. The best predictive REVEAL value in elderly patients (IPAH patients ≥ 60 years) was AUC 0.73 (0.56–0.91), p = 0.03; and in patients with LHD comorbidities in the entire cohort, it was AUC 0.73 (0.59–0.87), p < 0.009. Factors independently associated with death in the entire cohort were CKD (p = 0.01, HR 0.2), the right-to-left ventricle dimension ratio (p = 0.0047, HR 5.97), and NT-proBNP > 1400 pg/mL (p = 0.008, HR 3.18). Conclusion: Risk stratification in the elderly IPAH patients requires a fundamentally different approach than that of younger patients, taking into account the initial limitations in physical performance and comorbidities that interfere with current assessment scores. The REVEAL score reliably stratifies patients at any age and LHD comorbidities. The initial monotherapy seems to be reasonable in patients over 60 years. Selection tools for initial combination PAH therapy in older IPAH patients with comorbidities need to be validated in prospective observational studies.

7 May 2021 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
NMN. V. Marukyan
N. V. Marukyan
MSM. A. Simakova
M. A. Simakova
DZD. D. Zubarev
D. D. Zubarev
OMOlga Moiseeva
Olga Moiseeva
This review presents an analysis of recent publications on the principles of diagnosis and management of patients with chronic thromboembolic pulmonary hypertension (CTEPH). The authors emphasize the importance of patient's operability assessment regarding the possibility of performing pulmonary thrombendarterectomy - a radical treatment option due to complete post-thrombotic material removal from the branches of the pulmonary artery. In the case of an inoperable type of CTEPH, such a method of transcatheter treatment as step-by-step balloon angioplasty of the pulmonary artery (BPA) is proposed. The article clearly outlines the principles of selection, patient training and techniques for BPA. The authors demonstrated their own patented method of the peripheral vascular bed visualization in the case of recanalization of chronic occlusions, which increases the safety of this intervention. Particular attention is paid to hybrid approaches using a soluble guanylate cyclase stimulator, riociguate in combination with BPA for high risk CTEPH patients. The review presents the data of the post hoc analysis of the CHEST-1 study and the data of real clinical practice of the use of riociguat in combination with the endovascular method of treatment on the example of the leading expert groups in Europe, who demonstrated in their studies the positive effect of riociguat on the hemodynamic parameters and the frequency of perioperative complications.

25 June 2020 in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
Verified
Journal Article
Open access
PDF file
MSM. A. Simakova
M. A. Simakova
NGNatalia Sergeevna Goncharova
Natalia Sergeevna Goncharova
DKD. V. Karpova
D. V. Karpova
EKE. V. Karelkina
E. V. Karelkina
OMO. M. Moiseeva
O. M. Moiseeva
Pulmonary hypertension patients are extremely sensitive to intercurrent respiratory infections which can cause disease progression and bring an adverse outcome closer. The absence of specific symptoms and typical clinical manifestations of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension makes it difficult to verify such diagnosis in time for early specific therapy prescription. This problem becomes more significant during the COVID-19 pandemic. This review presents diagnostic algorithms for differential diagnosis of pulmonary hypertension in a patient with suspected COVID-19 infection. In this term computed tomography (CT) of the chest deserves high attention. Differential diagnostic criteria for “frosted glass” type changes at CT-scan have been developed and can be used in everyday practice. Besides this, the article describes the principles of pulmonary arterial hypertension optimal therapy choice, taking into account drug interactions and complications occurring in COVID-19 patients.